JP2005530705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530705A5 JP2005530705A5 JP2003574198A JP2003574198A JP2005530705A5 JP 2005530705 A5 JP2005530705 A5 JP 2005530705A5 JP 2003574198 A JP2003574198 A JP 2003574198A JP 2003574198 A JP2003574198 A JP 2003574198A JP 2005530705 A5 JP2005530705 A5 JP 2005530705A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- thiazolidine
- alkyl
- substituted
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 125000004432 carbon atom Chemical group C* 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- -1 monosubstituted amino Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 6
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 230000037356 lipid metabolism Effects 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 4
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 4
- 230000004069 differentiation Effects 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 210000001789 adipocyte Anatomy 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 235000009200 high fat diet Nutrition 0.000 claims 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 2
- 210000000229 preadipocyte Anatomy 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical group O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 claims 1
- IGHXENSMRWDRKA-UHFFFAOYSA-N 5-[[2,5-difluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(OC)=C(F)C=C1C=C1SC(=O)NC1=O IGHXENSMRWDRKA-UHFFFAOYSA-N 0.000 claims 1
- GQNUPWWBBITQJA-UHFFFAOYSA-N 5-[[2-fluoro-4-methoxy-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(OC)=CC=C1C=C1SC(=O)NC1=O GQNUPWWBBITQJA-UHFFFAOYSA-N 0.000 claims 1
- TUMQVWIXFYQMPE-UHFFFAOYSA-N 5-[[3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O TUMQVWIXFYQMPE-UHFFFAOYSA-N 0.000 claims 1
- JUYPRBPAOWLCMA-UHFFFAOYSA-N 5-[[3-(1-benzyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(C(=O)N2CC=3C=CC=CC=3)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O JUYPRBPAOWLCMA-UHFFFAOYSA-N 0.000 claims 1
- ASTKCMGCWSLEGK-UHFFFAOYSA-N 5-[[3-(1-ethyl-3,3,5-trimethyl-2-oxoindol-6-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)C(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O ASTKCMGCWSLEGK-UHFFFAOYSA-N 0.000 claims 1
- AJWYRAPTULXKLY-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2,5-difluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=C(F)C=1)OC)=C(F)C=1C=C1SC(=O)NC1=O AJWYRAPTULXKLY-UHFFFAOYSA-N 0.000 claims 1
- CXFIOEDVSRZEQP-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-2-fluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC)=C(F)C=1C=C1SC(=O)NC1=O CXFIOEDVSRZEQP-UHFFFAOYSA-N 0.000 claims 1
- HWJYWTWTNWGEPW-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O HWJYWTWTNWGEPW-UHFFFAOYSA-N 0.000 claims 1
- BTDIBTFOEQGYNN-UHFFFAOYSA-N 5-[[3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)-5-fluoro-4-methoxyphenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=C(F)C=1)OC)=CC=1C=C1SC(=O)NC1=O BTDIBTFOEQGYNN-UHFFFAOYSA-N 0.000 claims 1
- OVGKEHDDXLFCLP-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3C(C)(C)CC(=O)N(C)C=3C=2)C)C(N(C)C)=CC=C1C=C1SC(=O)NC1=O OVGKEHDDXLFCLP-UHFFFAOYSA-N 0.000 claims 1
- GTWRJNHQYADCSI-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1,4,7-trimethyl-2,3-dioxoquinoxalin-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3N(C)C(=O)C(=O)N(C)C=3C=2)C)C(N(C)C)=CC=C1C=C1SC(=O)NC1=O GTWRJNHQYADCSI-UHFFFAOYSA-N 0.000 claims 1
- NBTOFQXOPMRLOR-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O NBTOFQXOPMRLOR-UHFFFAOYSA-N 0.000 claims 1
- NDSWOANBUNAJAY-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O NDSWOANBUNAJAY-UHFFFAOYSA-N 0.000 claims 1
- XYWRENBSTJWTMP-UHFFFAOYSA-N 5-[[4-(dimethylamino)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)N(C)C)=CC=1C=C1SC(=O)NC1=O XYWRENBSTJWTMP-UHFFFAOYSA-N 0.000 claims 1
- FQHFXXCZTRYANX-UHFFFAOYSA-N 5-[[4-(ethylamino)-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=2C(=CC=3C(C)(C)CC(=O)N(CC)C=3C=2)C)C(NCC)=CC=C1C=C1SC(=O)NC1=O FQHFXXCZTRYANX-UHFFFAOYSA-N 0.000 claims 1
- RPBRNECKATZCRH-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1-propylindol-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)C(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O RPBRNECKATZCRH-UHFFFAOYSA-N 0.000 claims 1
- MXULYIDUFRFMCN-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(3,3,5-trimethyl-2-oxo-1h-indol-6-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=CC(C(C(=O)N2)(C)C)=C2C=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O MXULYIDUFRFMCN-UHFFFAOYSA-N 0.000 claims 1
- RXSDNKZJROLXLW-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propan-2-yl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C(C)C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O RXSDNKZJROLXLW-UHFFFAOYSA-N 0.000 claims 1
- KBJIHTLGARZNBW-UHFFFAOYSA-N 5-[[4-(trifluoromethoxy)-3-(4,4,6-trimethyl-2-oxo-1-propyl-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CCC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)OC(F)(F)F)=CC=1C=C1SC(=O)NC1=O KBJIHTLGARZNBW-UHFFFAOYSA-N 0.000 claims 1
- JMABEOVVSGPWJR-UHFFFAOYSA-N 5-[[4-chloro-3-(1,4,4,6-tetramethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(C)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)Cl)=CC=1C=C1SC(=O)NC1=O JMABEOVVSGPWJR-UHFFFAOYSA-N 0.000 claims 1
- JNBZPXIGSUERNY-UHFFFAOYSA-N 5-[[4-chloro-3-(1-ethyl-4,4,6-trimethyl-2-oxo-3h-quinolin-7-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C2N(CC)C(=O)CC(C)(C)C2=CC(C)=C1C(C(=CC=1)Cl)=CC=1C=C1SC(=O)NC1=O JNBZPXIGSUERNY-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical class [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- 229940043237 diethanolamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940012017 ethylenediamine Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 235000019371 penicillin G benzathine Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims 1
- 229940006486 zinc cation Drugs 0.000 claims 1
- 0 C=C(*C(*1)=O)C1=O Chemical compound C=C(*C(*1)=O)C1=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36270202P | 2002-03-08 | 2002-03-08 | |
| PCT/US2003/006784 WO2003075924A1 (en) | 2002-03-08 | 2003-03-07 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530705A JP2005530705A (ja) | 2005-10-13 |
| JP2005530705A5 true JP2005530705A5 (https=) | 2006-02-23 |
Family
ID=27805215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574198A Pending JP2005530705A (ja) | 2002-03-08 | 2003-03-07 | 糖尿病および他の疾患を治療するための複素環アミド誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7102000B2 (https=) |
| EP (1) | EP1487443A4 (https=) |
| JP (1) | JP2005530705A (https=) |
| KR (1) | KR20050006126A (https=) |
| CN (1) | CN1649586A (https=) |
| AU (1) | AU2003225682A1 (https=) |
| CA (1) | CA2478342A1 (https=) |
| IL (1) | IL163952A0 (https=) |
| MX (1) | MXPA04008733A (https=) |
| NO (1) | NO20044250L (https=) |
| RU (1) | RU2004129752A (https=) |
| TW (1) | TW200306184A (https=) |
| WO (1) | WO2003075924A1 (https=) |
| ZA (1) | ZA200408057B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517993A (en) | 1999-08-31 | 2004-03-26 | Incyte San Diego Inc | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| IL157740A0 (en) * | 2001-03-07 | 2004-03-28 | Incyte San Diego Inc | Heterocyclic derivatives and pharmaceutical compositions containing the same |
| US7265139B2 (en) * | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
| WO2003016267A1 (en) * | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| CN1774246A (zh) * | 2003-04-18 | 2006-05-17 | 因齐特圣迭戈公司 | 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物 |
| EP1566202A1 (en) * | 2004-02-23 | 2005-08-24 | Sahltech I Göteborg AB | Use of resistin antagonists in the treatment of rheumatoid arthritis |
| US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| ATE464564T1 (de) * | 2004-08-30 | 2010-04-15 | Takeda Pharmaceutical | Screening-verfahren |
| US7638533B2 (en) | 2005-09-30 | 2009-12-29 | Janssen Pharmaceutica N.V. | Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| ATE536347T1 (de) | 2008-05-20 | 2011-12-15 | Merck Sharp & Dohme | Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren |
| JP6014816B2 (ja) | 2011-05-10 | 2016-10-26 | 国立大学法人神戸大学 | Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体 |
| US10449254B2 (en) * | 2013-11-03 | 2019-10-22 | The Regents Of The University Of California | Ionic liquids for transdermal drug delivery |
| EP3467459B1 (en) * | 2016-06-07 | 2020-11-25 | Mitsubishi Electric Corporation | Temperature estimation method |
| JP7179354B2 (ja) | 2016-08-29 | 2022-11-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 皮膚処置のためのイオン種に基づく局所処方物 |
| US10828265B2 (en) | 2016-12-09 | 2020-11-10 | The Regents Of The University Of California | Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| JPS5538359A (en) | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| US4713244A (en) | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4931279A (en) | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
| CA1325222C (en) | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
| JP2539504B2 (ja) | 1987-03-11 | 1996-10-02 | 鐘淵化学工業株式会社 | ヒドロキシスチレン誘導体 |
| FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| JPS63230689A (ja) * | 1987-03-18 | 1988-09-27 | Tanabe Seiyaku Co Ltd | ベンゾオキサジン誘導体 |
| US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| IE62214B1 (en) | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| ATE173728T1 (de) | 1991-07-22 | 1998-12-15 | Pfizer | Verfahren zur herstellung von (s)-4-(3-(5-methyl- 2-phenyl-4-oxazolyl)- 1-hydroxypropyl> brombenzol |
| DE10199033I2 (de) | 1992-04-22 | 2003-01-09 | Ligand Parmaceuticals Inc | Retinoid-x Rezeptor selektive Verbindungen |
| US5780676A (en) | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| EP0915090A1 (en) | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
| JPH08506323A (ja) | 1992-11-25 | 1996-07-09 | ラ ホヤ キャンサー リサーチ ファウンデーション | Ｒｘｒホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用 |
| DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| AU692839B2 (en) | 1994-02-17 | 1998-06-18 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
| US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
| JPH09136877A (ja) | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
| EP0850067A4 (en) | 1995-07-17 | 1999-12-15 | Cird Galderma | METHODS OF TREATING CANCER USING 6- 3- 1-ADAMANTYL] -4-HYDROXYPHENYL] |
| JPH09176162A (ja) | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| EP0844997A1 (en) | 1996-06-19 | 1998-06-03 | Dr. Reddy's Research Foundation | Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation |
| IL127946A0 (en) | 1996-07-08 | 2000-02-17 | Cird Galderma | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents |
| WO1999009965A2 (en) | 1997-08-21 | 1999-03-04 | Takeda Chemical Industries, Ltd. | Anti-inflammatory agent |
| JP4398585B2 (ja) | 1997-11-12 | 2010-01-13 | 有限会社ケムフィズ | レチノイドレセプター作用剤 |
| US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| ID27787A (id) | 1998-08-21 | 2001-04-26 | Viro Pharma Inc | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan |
| WO2000018748A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000032598A1 (en) | 1998-12-04 | 2000-06-08 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| NZ517993A (en) | 1999-08-31 | 2004-03-26 | Incyte San Diego Inc | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| KR100608416B1 (ko) | 1999-11-12 | 2006-08-02 | 후지모토 쿄다이 가부시키가이샤 | 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체 |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| IL157740A0 (en) | 2001-03-07 | 2004-03-28 | Incyte San Diego Inc | Heterocyclic derivatives and pharmaceutical compositions containing the same |
| US7265139B2 (en) | 2001-03-08 | 2007-09-04 | Incyte San Diego Inc. | RXR activating molecules |
| EP1373240B1 (en) | 2001-03-14 | 2005-06-15 | Eli Lilly And Company | Retinoid x receptor modulators |
| JP4590158B2 (ja) | 2001-04-04 | 2010-12-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法 |
| WO2003016267A1 (en) | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| AU2002352706A1 (en) * | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
| TW200304375A (en) | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
| US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| US20050014767A1 (en) | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
| CN1774246A (zh) | 2003-04-18 | 2006-05-17 | 因齐特圣迭戈公司 | 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物 |
-
2003
- 2003-03-06 US US10/384,352 patent/US7102000B2/en not_active Expired - Fee Related
- 2003-03-07 ZA ZA200408057A patent/ZA200408057B/en unknown
- 2003-03-07 EP EP03744197A patent/EP1487443A4/en not_active Withdrawn
- 2003-03-07 WO PCT/US2003/006784 patent/WO2003075924A1/en not_active Ceased
- 2003-03-07 RU RU2004129752/04A patent/RU2004129752A/ru not_active Application Discontinuation
- 2003-03-07 JP JP2003574198A patent/JP2005530705A/ja active Pending
- 2003-03-07 KR KR10-2004-7014099A patent/KR20050006126A/ko not_active Withdrawn
- 2003-03-07 CN CNA038101483A patent/CN1649586A/zh active Pending
- 2003-03-07 IL IL16395203A patent/IL163952A0/xx unknown
- 2003-03-07 CA CA002478342A patent/CA2478342A1/en not_active Abandoned
- 2003-03-07 AU AU2003225682A patent/AU2003225682A1/en not_active Abandoned
- 2003-03-07 TW TW092105025A patent/TW200306184A/zh unknown
- 2003-03-07 MX MXPA04008733A patent/MXPA04008733A/es unknown
-
2004
- 2004-10-07 NO NO20044250A patent/NO20044250L/no unknown
-
2006
- 2006-06-28 US US11/476,330 patent/US20060241138A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530705A5 (https=) | ||
| JP2005525371A5 (https=) | ||
| JP2817840B2 (ja) | 置換チアゾリジンジオン誘導体の製造方法 | |
| CN1065863C (zh) | N-取代二氧代噻唑烷基苯甲酰胺衍生物及其制备方法 | |
| US5391565A (en) | Oxazolidine dione derivatives | |
| RU2004129752A (ru) | Гетероциклические амидные промзводные для лечения диабета и других заболеваний | |
| US4918091A (en) | Novel thiazolidinediones | |
| JP2005513026A5 (https=) | ||
| US5075300A (en) | Novel compounds | |
| RU98117628A (ru) | Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция | |
| NZ609955A (en) | Sgc stimulators | |
| JP2007523905A5 (https=) | ||
| US5599826A (en) | Thiazolidinediones and drugs containing them | |
| JP2005511608A5 (https=) | ||
| HUT70153A (en) | Hypoglycemic hydroxyurea derivatives | |
| JP2972377B2 (ja) | カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物 | |
| JP2011502958A5 (https=) | ||
| EP1487446A2 (en) | Bicyclic heterocycles for the treatment of diabetes and other diseases | |
| CN1121690A (zh) | 噻唑烷二酮在治疗动脉粥样硬化和摄食性疾病方面的用途 | |
| JP2005511516A5 (https=) | ||
| JP2013507397A5 (https=) | ||
| WO2001036402A1 (en) | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives | |
| TW487707B (en) | Improved process for the production of thiazolidinediones and new thiazolidinediones | |
| US6680387B2 (en) | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | |
| JP2007531763A5 (https=) |